Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.
Also called NCT02055976
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 218 participants
- Sponsor
- Registry
-
NCT02055976
-
- Other papers using this trial's data
- Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02055976. Randomized; triple masking; primary purpose treatment. Start 2014-03 (actual); primary completion 2015-01 (actual). Results posted on 2019-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct02055976- Content hash
b2c38ca8d47f3b23e2307728f80d43964befc801925cc59320d378f4d7ee25ea